Sun Pharma Advanced Research Company is currently trading at Rs. 149.70, up by 1.35 points or 0.91% from its previous closing of Rs. 148.35 on the BSE.
The scrip opened at Rs. 148.05 and has touched a high and low of Rs. 163.05 and Rs. 148.05 respectively. So far 335073 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 204.25 on 02-Jun-2025 and a 52 week low of Rs. 108.20 on 23-Mar-2026.
Last one week high and low of the scrip stood at Rs. 163.05 and Rs. 114.00 respectively. The current market cap of the company is Rs. 4867.82 crore.
The promoters holding in the company stood at 65.67%, while Institutions and Non-Institutions held 2.91% and 31.42% respectively.
Sun Pharma Advanced Research Company (SPARC) has entered into a definitive asset purchase agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for $195 million upon the closing of the transaction. PRV was granted by the U.S. Food and Drug Administration (FDA) for the approval of Sezaby indicated for the treatment of neonatal seizures.
The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Stifel acted as the exclusive financial advisor to SPARC with respect to this transaction.
Sun Pharma Advanced Research Company is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 477.50 |
| Indegene | 534.20 |
| CMS Info Systems | 290.30 |
| JITF Infralogistics | 294.30 |
| Sagility | 41.62 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: